White Paper

Rapid Change Is Everywhere In Today's Pharma and Biotech Industry. Meaningful Innovation Is Not.

Source: Asymchem
capsule science elements inspect

As the pace of change in the pharma and biotech industry continues to accelerate, companies are increasingly relying on CDMOs to help them meet complex challenges and capitalize on fast-evolving opportunities. CDMOs have responded in a variety of ways—adding specialized services via mergers and acquisition, making forays into biologics, or expanding their capabilities across the drug lifecycle.

In all of these cases, CDMOs face the challenge of integrating novel technologies—technologies that are either new to the CDMO or new to the industry—to deliver cost-effective innovation to the market. But developing and applying novel technologies can be a costly and complex undertaking. Roadblocks and setbacks are an inevitable frustration of doing something new. How a CDMO responds to the unexpected can determine the success or failure of a project.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online